

Cardiovascular Disease

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

Trial Status
Not yet recruiting

Trial Runs In

Trial Identifier
NCT07843472 2026-526190-41-00
CC46446

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide Vs. Placebo in Participants With Overweight Or Obesity And Established Cardiovascular Disease

Trial Summary:

This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT07843472 2026-526190-41-00 CC46446
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
#40 Years

Healthy Volunteers
No

Inclusion Criteria:

- Participants with BMI # 27 kg/m² and established CVD
- History of at least one self-reported unsuccessful dietary effort to lose body weight

ForPatients

by Roche

Exclusion Criteria:

- Known history of Type 1 diabetes mellitus
- Current or previous treatment with petrelintide or any other amylin analog